(Q38700644)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2677939%20AND%20SRC:MED&resulttype=core&format=json

3 October 2019

review article

1 reference

title

Clinical pharmacology of cancer chemotherapy in children (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2677939%20AND%20SRC:MED&resulttype=core&format=json

3 October 2019

1 reference

W E Evans

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2677939%20AND%20SRC:MED&resulttype=core&format=json

3 October 2019

W P Petros

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2677939%20AND%20SRC:MED&resulttype=core&format=json

3 October 2019

M V Relling

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2677939%20AND%20SRC:MED&resulttype=core&format=json

3 October 2019

W R Crom

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2677939%20AND%20SRC:MED&resulttype=core&format=json

3 October 2019

T Madden

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2677939%20AND%20SRC:MED&resulttype=core&format=json

3 October 2019

J H Rodman

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2677939%20AND%20SRC:MED&resulttype=core&format=json

3 October 2019

M Sunderland

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2677939%20AND%20SRC:MED&resulttype=core&format=json

3 October 2019

publication date

1 October 1989

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2677939%20AND%20SRC:MED&resulttype=core&format=json

Pediatric Clinics of North America

3 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2677939%20AND%20SRC:MED&resulttype=core&format=json

3 October 2019

volume

36

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2677939%20AND%20SRC:MED&resulttype=core&format=json

3 October 2019

page(s)

1199-1230

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2677939%20AND%20SRC:MED&resulttype=core&format=json

3 October 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2677939%20AND%20SRC:MED&resulttype=core&format=json

Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine

3 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotoxin glucopyranoside derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Bioavailability of low-dose vs high-dose 6-mercaptopurine

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

The effect of methotrexate on the bioavailability of oral 6-mercaptopurine

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Plasma levels of doxorubicin after IV bolus injection and infusion of the doxorubicin-DNA complex in rabbits and man. Comparison with free doxorubicin

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Pharmacokinetics and metabolism of adriamycin in man

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Adriamycin chemotherapy--efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule.

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Treatment of children with refractory acute lymphocytic leukemia with vincristine and diltiazem.

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Reduction in central nervous system leukemia with a pharmacokinetically derived intrathecal methotrexate dosage regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Adriamycin. A new anticancer drug with significant clinical activity

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Systemic clearance of methotrexate in the prognosis of acute lymphoblastic leukemia in children

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Ifosfamide--pharmacology, safety and therapeutic potential

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Allogeneic bone marrow transplantation after hyperfractionated total-body irradiation and cyclophosphamide in children with acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Dosage predictions in high-dose methotrexate infusions. Part 2: Bayesian estimation of methotrexate clearance.

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Pharmacokinetics of teniposide (VM 26) after IV administration in serum and malignant ascites of patients with ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Dosage predictions in high-dose methotrexate infusions. Part 1: Evaluation of the classic test-dose protocol.

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

1 reference

7 January 2021

Effect of hydration on methotrexate plasma concentrations in children with acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

The clinical pharmacology of etoposide and teniposide

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Tumor-inhibitory effects of combinations of the vinca alkaloids with actinomycin D

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

The clinical pharmacology of VM26 and VP16-213. A brief overview

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Pharmacokinetics of anticancer drugs in children

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Can severe vincristine neurotoxicity be prevented?

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

High-performance liquid chromatographic determination of vinca-alkaloids in plasma and urine

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Effect of pleural effusion on high-dose methotrexate kinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Pharmacokinetics of Sustained Serum Methotrexate Concentrations Secondary to Gastrointestinal Obstruction

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Methotrexate systemic clearance influences probability of relapse in children with standard-risk acute lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Clinical pharmacodynamics of anticancer drugs: a basis for extending the concept of dose-intensity

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Dose: a critical factor in cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Dechloroethylation of ifosfamide and neurotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Clinical pharmacology of high-dose etoposide associated with cisplatin. Pharmacokinetic and metabolic studies

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Serum and tissue concentrations of doxorubicin after IV administration of doxorubicin or doxorubicin-DNA complex to patients with gastrointestinal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Reduction of vincristine toxicity by Cronassial

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

6-Mercaptopurine: apparent lack of relation between prescribed dose and biological effect in children with leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Pharmacokinetics of high dose etoposide (VP 16-213)

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Circadian timing of cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Etoposide (VP16-213) and teniposide (VM26) comparative in vitro activities in human tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

The podophyllotoxin derivatives VP16-213 and VM26.

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Clinical trial of pyridoxine to reduce vincristine neurotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Clinical trial of folinic acid to reduce vincristine neurotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Synthesis and antimitotic activity of glycosidic lignan derivatives related to podophyllotoxin

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Test dose for predicting high-dose methotrexate infusions

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Comparison of intermittent or continuous methotrexate plus 6-mercaptopurine in regimens for standard-risk acute lymphoblastic leukemia in childhood (JCCLSG-S811). The Japanese Children's Cancer and Leukemia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Cellular pharmacokinetics of daunorubicin: relationships with the response to treatment in patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

A Pharmacokinetic Evaluation of Free and DNA-Complexed Adriamycin: A Preliminary Study in Children with Malignant Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Large interindividual variations in the pharmacokinetics of oral 6-mercaptopurine in maintenance therapy of children with acute leukaemia and non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Pharmacokinetic case for giving 6-mercaptopurine maintenance doses at night

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Oral 6-mercaptopurine in childhood leukemia: parent drug pharmacokinetics and active metabolite concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Are children with lymphoblastic leukaemia given enough 6-mercaptopurine?

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

When is autologous bone marrow transplantation safe after high-dose treatment with etoposide?

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Hypersensitivity reactions to teniposide (VM-26): an analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Physician compliance and relapse rates of acute lymphoblastic leukemia in children.

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Pharmacologic studies of intra-hepatic artery chemotherapy with degradable starch microspheres.

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Are children with lymphoblastic leukaemia resistant to 6-mercaptopurine because of 5'-nucleotidase?

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Drug dosage and remission duration in childhood lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

6-Mercaptopurine dosage

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Continuous vincristine infusion as part of a high dose chemoradiotherapy regimen: drug kinetics and toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Relationship between leukemic cell retention of cytosine arabinoside triphosphate and the duration of remission in patients with acute non-lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

High-dose cytarabine and total body irradiation with or without cyclophosphamide as a preparative regimen for marrow transplantation for acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Bilary disposition of adriamycin

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Maintenance chemotherapy for childhood acute lymphoblastic leukaemia: better in the evening

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Response of L1210 to combinations of cytosine arabinoside and VM-26 or VP16-213

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

VM-26 and cytosine arabinoside combination chemotherapy for initial induction failures in childhood lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Pharmacokinetics of adriamycin in patients with breast cancer: correlation between pharmacokinetic parameters and clinical short-term response.

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Doxorubicin clearance in the obese

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Reduced citrovorum factor rescue for high-dose methotrexate therapy in childhood malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Pharmacokinetics of erythrocyte methotrexate in children with acute lymphoblastic leukemia during maintenance treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Repeated high-dose cyclophosphamide administration in bone marrow transplantation: exposure to activated metabolites

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Pharmacokinetics of vincristine sulfate in children

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Mesna and oxazaphosphorine cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Etoposide: A Semisynthetic Epipodophyllotoxin Chemistry, Pharmacology, Pharmacokinetics, Adverse Effects and Use as an Antineoplastic Agent

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

The pharmacokinetics of cytosine arabinoside in the plasma and cerebrospinal fluid during conventional and high-dose therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Cellular and plasma adriamycin concentrations in long-term infusion therapy of leukemia patients

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Plasma and cellular adriamycin concentrations in patients with myeloma treated with ninety-six-hour continuous infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Clinical pharmacokinetics of doxorubicin

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Altered protein binding of etoposide in patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Use of Plasma Pharmacokinetics to Predict and Prevent Methotrexate Toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Pharmacokinetic determinants of 6-mercaptopurine myelotoxicity and therapeutic failure in children with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

(2"-R)-4'-o-tetrahydropyranyladriamycin, a new anthracycline derivative; its effectiveness in lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Methotrexate bioavailability after oral and intramuscular administration in children

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

The anticancer agent adriamycin can be actively cytotoxic without entering cells

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

A model for the action of vinblastine in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Pharmacokinetics of "activated" cyclophosphamide and therapeutic efficacies

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Risk factors for doxorubicin-induced congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Direct resolution of the stereoisomers of leucovorin and 5-methyltetrahydrofolate using a bovine serum albumin high-performance liquid chromatographic chiral stationary phase coupled to an achiral phenyl column

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Vincristine infusion. A phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Experience with the use of adriamycin in combination with other anticancer agents using a weekly schedule, with particular reference to lack of cardiac toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Neurotoxicity of commonly used antineoplastic agents (second of two parts).

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Membrane transport influences the rate of accumulation of cytosine arabinoside in human leukemia cells

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Cytosine arabinoside transport by human leukaemic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Cytosine arabinoside transport and metabolism in acute leukemias and T cell lymphoblastic lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Action of drugs on microtubules

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

High-dose VP-16-213 and autologous bone marrow transplantation for refractory malignancies: a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

High-dose VP-16-213 monotherapy for refractory germinal malignancies: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

In vitro pharmacodynamic evaluation of VP-16-213 and implications for chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Life-threatening neuropathy and hepatotoxicity in infants during induction therapy for acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

1 reference

7 January 2021

Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered?

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

Etoposide pharmacokinetics in patients with normal and abnormal organ function

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936765-7

7 January 2021

10.1016/S0031-3955(16)36765-7

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2677939%20AND%20SRC:MED&resulttype=core&format=json

3 October 2019

1 reference